Skip to main
PTHS

PTHS Stock Forecast & Price Target

PTHS Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Pelthos Therapeutics is experiencing significant momentum in its prescription growth, with October reporting a remarkable 41% increase over the previous month and surpassing the entire third-quarter volume within the initial weeks of the fourth quarter. The company's proactive strategy to expand its sales force from 50 to 64 territory managers aims to enhance engagement with an increasing target base of approximately 10,000 clinicians, indicating a strong potential for market penetration. Furthermore, with management's focus on capturing share in the sizable impetigo market, Pelthos stands to benefit from high operating leverage in its commercial model, positioning it favorably for revenue growth in the coming quarters.

Bears say

Pelthos Therapeutics Inc. faces significant challenges that contribute to a negative outlook, primarily related to potential issues with market adoption, competition, and financial stability. If the company fails to secure adequate reimbursement, formulary placement, or affordability programs, it may experience lower-than-expected revenue growth, impacting projections significantly. Furthermore, risks associated with funding, partner execution, and possible disruptions in clinical and operational processes could hinder progress and delay key initiatives, adding to the uncertainty surrounding Pelthos' financial outlook.

PTHS has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pelthos Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pelthos Therapeutics Inc (PTHS) Forecast

Analysts have given PTHS a Strong Buy based on their latest research and market trends.

According to 4 analysts, PTHS has a Strong Buy consensus rating as of Jan 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $56.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $56.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pelthos Therapeutics Inc (PTHS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.